Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-996 in overweight/obese participants and type 2 diabetes
NCT05814107Phase 1Completed
- Sponsor
- Carmot Therapeutics
- Start
- May 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of CT-996 in type 2 diabetes mellitus (T2DM) and obesity (13 arms), sponsored by Carmot Therapeutics. Primary endpoint: Treatment-Emergent Adverse Events at 58 days. Started May 2023; status: completed.
02
Drugs
CT-996
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05814107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05814107.